Patent: 7,976,852
✉ Email this page to a colleague
Summary for Patent: 7,976,852
Title: | Compositions and methods for cancer immunotherapy |
Abstract: | The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer. |
Inventor(s): | Rossignol; Daniel P. (Ridgefield Park, NJ), Ishizaka; Sally T. (Weston, MA), Hawkins; Lynn D. (Concord, MA), Fields; Scott Z. (Towaco, NJ) |
Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
Application Number: | 11/411,332 |
Patent Claims: | see list of patent claims |
Details for Patent 7,976,852
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-03-29 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-03-29 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |